Researchers reviewing 196 studies found promising AI applications for donor organ assessment, surgical planning, and transplant monitoring, but only a small fraction of the systems have undergone independent clinical validation.

WHAT’S HAPPENING

Artificial intelligence is showing promise across nearly every stage of liver transplantation, from deciding which patients may benefit from surgery to monitoring complications after a transplant.

A comprehensive review published October 23, 2026, in PLOS ONE examined 196 studies investigating AI applications in liver transplantation.

Researchers identified potential uses involving donor organ assessment, patient selection, surgical planning, postoperative monitoring, and long-term treatment.

The findings suggest that AI could help physicians analyze complicated medical information and identify risks that conventional assessment methods might overlook.

Among the applications examined:

• Patient selection: Estimating transplant risks and predicting outcomes for potential recipients.

• Donor organ evaluation: Analyzing medical images and clinical information to assess liver quality.

• Surgical planning: Supporting anatomical assessment and anticipating possible complications.

• Postoperative monitoring: Predicting organ rejection, graft failure, and patient survival.

• Medication management: Supporting decisions involving drugs used to prevent transplant rejection.

However, the review uncovered a significant limitation.

Only 13.8% of the studies independently validated their AI models using external data.

Approximately 96% relied on retrospective research, analyzing information from patients who had already received medical care.

Just one study evaluated an AI application through a randomized controlled trial.

The central finding is that AI research in liver transplantation is expanding, but most proposed systems have not yet demonstrated reliable performance in real-world clinical settings.

WHY IT MATTERS

Liver transplantation involves some of the most complicated decisions in medicine.

Physicians must determine which patients are suitable candidates, assess scarce donor organs, plan complex surgical procedures, and manage potentially serious complications.

The consequences of inaccurate decisions can be substantial.

AI could potentially help by identifying patterns across medical images, laboratory results, patient histories, and clinical outcomes.

For example, an AI model might identify factors associated with a higher risk of organ rejection or complications following surgery.

Such information could help clinicians make more informed decisions.

But there is a difference between accurately analyzing historical medical records and improving treatment outcomes for patients receiving care today.

An AI model developed using information from one hospital may perform differently at another institution.

Differences in patient populations, clinical procedures, available equipment, and medical practices can affect results.

That makes independent testing essential.

A model that performs well in research is not automatically a model that hospitals can safely rely on.

The review highlights the importance of evaluating AI systems across multiple institutions and determining whether their use actually improves patient care.

It also illustrates a broader challenge facing medical AI.

Developers can produce promising algorithms faster than healthcare institutions can establish the clinical evidence needed for widespread adoption.

WHO BENEFITS

– Transplant patients: Could eventually benefit from more accurate risk assessment, improved monitoring, and better-informed treatment decisions.

– Transplant surgeons and physicians: May gain additional tools for evaluating donor organs, planning procedures, and anticipating complications.

– Hospitals and transplant centers: Could benefit from clinically validated systems that improve decision-making and resource utilization.

– Medical AI developers: Gain opportunities to develop specialized tools for transplant medicine and other complex medical procedures.

– Clinical research organizations: May see increased demand for independent validation, multicenter studies, and real-world AI evaluations.

WHO LOSES

– Developers relying on limited research datasets: May struggle to demonstrate that their systems work reliably across different hospitals.

– Healthcare technology companies without clinical evidence: Could face adoption barriers when hospitals require independently validated results.

– Hospitals adopting insufficiently tested systems: Risk inaccurate predictions and potentially harmful clinical decisions.

– Patients exposed to unreliable AI recommendations: Could face unnecessary risks if automated predictions are treated as established clinical evidence.

WHAT HAPPENS NEXT

The next important development will be moving AI transplantation research from retrospective studies into carefully evaluated clinical applications.

Researchers will need to test models using data from hospitals that were not involved in their development.

Larger multicenter studies could help determine whether systems remain accurate across different patient populations.

Prospective clinical trials will also be necessary to establish whether AI-assisted decisions produce better outcomes than existing medical practices.

Another priority will be determining how AI systems integrate into hospital workflows.

A reliable prediction is only useful if physicians can interpret it, understand its limitations, and apply it appropriately.

For healthcare technology companies, this creates an important commercial distinction.

Developing an AI model is one challenge.

Demonstrating that the model is safe, dependable, and clinically beneficial is another.

Businesses capable of providing that evidence may be better positioned to secure hospital partnerships and support wider adoption.

The broader lesson extends beyond liver transplantation.

Across healthcare, AI technologies are advancing rapidly, while clinical validation remains a critical requirement for responsible implementation.

The larger shift is clear: Artificial intelligence could become a valuable tool throughout the liver transplantation process, but promising research results are not enough. The next major advance will come when AI systems demonstrate that they can improve real patient outcomes across different hospitals. In medical AI, the ability to prove reliability may ultimately be as important as the technology itself.